Meeting
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
Authors
Joan Miguel Romero
Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Joan Miguel Romero , Emma Titmuss , Yifan Wang , James Vafiadis , Alain Pacis , Gun Ho Jang , Amy Zhang , Bryn Golesworthy , Tatiana Lenko , Laura Williamson , Barbara Grunwald , Grainne M. O'Kane , Julie Wilson , Steven Gallinger , Janessa J. Laskin , George Zogopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Inflammatory Signatures
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2558)
DOI
10.1200/JCO.2022.40.16_suppl.2558
Abstract #
2558
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2022 ASCO Annual Meeting
Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
First Author: Annika Lenz
Poster
2021 ASCO Annual Meeting
High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.
First Author: Andreas Seeber
Poster
2019 ASCO Annual Meeting
Tumor mutation burden and PD-L1 expression in SDH/FH mutated solid tumors.
First Author: Leylah Drusbosky